A specially engineered antibody that can accurately deliver RNA treatments into hard-to-reach and hard-to-treat tumors significantly improved survival and reduced tumor sizes in animal models ...

Bispecific T‑cell engagers now dominate oncology pipelines, with global trial activity up 256% since 2019. FDA has approved more than 15 such drugs, and U.S. spending is projected to hit $12 ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

Novartis ended work on ianalumab in a painful skin condition after the antibody failed to meet “predefined efficacy thresholds” in a phase 2 study.

Antibody-Based Therapies for the Treatment of Hodgkin Lymphoma in Older Patients The following represents disclosure information provided by authors of this manuscript. All relationships are ...

More than half of people who received a pair of broadly neutralising antibodies (bnAbs) plus the immune-modulating drug N-803 (Anktiva) had delayed viral rebound or maintained a low or suppressed ...

AUSTIN, Texas, July 29, 2025--ImmunoPrecise Antibodies Ltd. ("IPA", "Company", "we" or "us") (NASDAQ: IPA), a bio-native AI company operating at the intersection of TechBio and next-generation ...

Tamemoto, Y., et al. (2025). Antibody-dependent cellular cytotoxicity of anti-programmed death-ligand 1 antibodies for T cells attenuate their antitumor efficacy in a murine tumor model.

The Magic of Disney Animation is returning to Disney’s Hollywood Studios, but not in the same way guests remember.